By Counterforce Health Team in Vyondys 53 (golodirsen) —

How to Get Vyondys 53 (Golodirsen) Covered by Aetna CVS Health in New Jersey: Complete Coding, Prior Authorization, and Appeals Guide

Answer Box: Getting Vyondys 53 Covered by Aetna CVS Health in New Jersey

Vyondys 53 (golodirsen) requires prior authorization from Aetna CVS Health with genetic testing confirming exon 53-amenable DMD mutation (ICD-10: G71.01), prescribed by a neuromuscular specialist, with baseline kidney function labs. Use J-code J1429 (10 mg units) under medical benefit. If denied, complete Aetna's internal appeals, then file with New Jersey's IHCAP within 120 days for external review with ~50% overturn success rate.

First step today: Contact CVS Specialty Pharmacy at 1-800-237-2767 to initiate prior authorization while your neuromuscular specialist prepares the precertification packet.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit
  2. ICD-10 Mapping for DMD
  3. HCPCS J-Code and NDC Requirements
  4. Clean Prior Authorization Anatomy
  5. Frequent Coding Pitfalls
  6. Aetna CVS Health Verification
  7. Quick Audit Checklist
  8. New Jersey Appeals Process
  9. FAQ

Coding Basics: Medical vs. Pharmacy Benefit

Vyondys 53 (golodirsen) is billed under the medical benefit, not pharmacy benefit, because it requires IV infusion in clinical settings like hospital outpatient departments or infusion centers. This distinction is crucial for proper reimbursement from Aetna CVS Health.

Medical Benefit Pathway

  • Primary codes: J1429 (golodirsen injection, 10 mg units) + CPT 96413 (IV infusion, up to 1 hour)
  • Site of care: Hospital outpatient, infusion center, or physician office with infusion capability
  • Prior authorization: Required through Aetna's medical benefit team, not CVS Caremark pharmacy

Why Not Pharmacy Benefit?

Unlike oral medications dispensed from specialty pharmacies, Vyondys 53's weekly IV infusion requires professional administration with a 0.2 micron filter over 35-60 minutes, making it a medical procedure rather than a dispensed medication.

ICD-10 Mapping for DMD

The primary diagnosis code for all Duchenne muscular dystrophy cases, including those with exon 53 mutations eligible for Vyondys 53, is G71.01 (Duchenne or Becker muscular dystrophy). This billable code became effective October 1, 2018, replacing broader classifications.

Documentation Requirements

Your medical records must include specific language that supports the G71.01 coding:

  • "Duchenne muscular dystrophy confirmed by genetic testing"
  • "Exon 53 deletion amenable to golodirsen therapy"
  • "Progressive proximal muscle weakness consistent with DMD"
  • "Elevated creatine kinase levels"

Supporting Codes

Consider these additional ICD-10 codes for comprehensive documentation:

  • I42.8: Cardiomyopathy (common DMD complication)
  • I49.8: Cardiac arrhythmias
  • Z14.01: Dystrophin gene mutation (for genetic screening context)

HCPCS J-Code and NDC Requirements

J1429 Billing Specifications

  • J-code: J1429 (Injection, golodirsen, 10 mg)
  • Billing unit: 1 unit = 10 mg of golodirsen
  • NDC number: 60923-0465-xx (100 mg/2 mL single-dose vial)
  • Effective date: July 1, 2020

Dosing and Unit Conversion

Vyondys 53 is dosed at 30 mg/kg body weight weekly. Here's how to calculate billing units:

Example: 40 kg patient

  • Total dose: 40 kg × 30 mg/kg = 1,200 mg
  • Billing units: 1,200 mg ÷ 10 mg/unit = 120 units of J1429
  • Vials needed: 1,200 mg ÷ 100 mg/vial = 12 vials

Administration Codes

  • 96413: IV infusion, initial service, up to 1 hour (primary)
  • 96415: Each additional hour (if infusion exceeds 1 hour)
  • Modifier -JW: Document drug waste/discard when applicable

Clean Prior Authorization Anatomy

A successful Aetna CVS Health prior authorization for Vyondys 53 includes these essential components:

Required Documentation Checklist

✓ Genetic testing report from CLIA-certified laboratory confirming exon 53-amenable mutation
✓ Neuromuscular specialist prescription with medical necessity letter
✓ Baseline labs: Cystatin C, urine protein/creatinine ratio
✓ Functional assessment: 6-minute walk test (≥250m preferred)
✓ Current weight for accurate 30 mg/kg dosing calculation
✓ Corticosteroid history (≥6 months stable dosing)
✓ Infusion plan specifying site of care and monitoring protocol

Medical Necessity Letter Elements

Your neuromuscular specialist's letter should address:

  1. FDA indication: Cite accelerated approval for exon 53-amenable DMD
  2. Genetic confirmation: Reference specific mutation details
  3. Clinical rationale: Progressive weakness, ambulatory status
  4. Prior treatments: Document corticosteroid use and response
  5. Consequences of delay: Potential functional decline
From our advocates: We've seen faster approvals when the genetic testing report explicitly states "amenable to exon 53 skipping therapy" rather than just listing the deletion. This specific language helps reviewers immediately understand eligibility without additional interpretation.

Frequent Coding Pitfalls

Common Errors That Cause Denials

Error Correction Impact
Using J3490/J3590 (unclassified) Use J1429 Automatic denial
Incorrect unit calculation 1 unit = 10 mg (not per vial) Payment rejection
Wrong administration CPT 96413/96415 (not 96365) Claim denial
Missing genetic specificity Document exon 53 amenability Medical necessity denial
Pharmacy benefit submission Submit under medical benefit Wrong benefit denial

Unit Conversion Mistakes

The most common error is confusing vial count with billing units. Remember:

  • Vials: 100 mg each (physical product)
  • Billing units: 10 mg each (J1429 definition)
  • Always calculate: Total mg ÷ 10 = billing units

Aetna CVS Health Verification

Pre-Submission Verification Steps

  1. Confirm PA requirement: Check Aetna's precertification list
  2. Verify J-code coverage: Ensure J1429 is on your plan's medical benefit formulary
  3. Check provider network: Confirm infusion site is in-network
  4. Review plan-specific criteria: Some Aetna plans have additional requirements

Submission Methods

  • Online: CVS Caremark provider portal (preferred)
  • Fax: 1-800-323-2445 or state-specific number
  • Phone: CVS Specialty Pharmacy at 1-800-237-2767

Counterforce Health can help analyze your specific plan's requirements and prepare targeted prior authorization requests that address common denial reasons before submission.

Quick Audit Checklist

Before submitting your Vyondys 53 prior authorization to Aetna CVS Health:

Patient Information

  • Aetna member ID and policy number verified
  • Patient weight documented for dosing calculation
  • Age at initiation (preferably <16 years)

Clinical Documentation

  • ICD-10 G71.01 with DMD diagnosis
  • CLIA-certified genetic testing confirming exon 53 amenability
  • Neuromuscular specialist credentials and consultation note
  • Baseline kidney function labs (cystatin C, UPCR)
  • Functional status (6MWT, NSAA scores if available)

Coding Accuracy

  • J1429 units calculated correctly (total mg ÷ 10)
  • NDC 60923-0465-xx matches vials ordered
  • Administration CPT 96413 for infusion
  • Modifier -JW for any documented waste

Submission Details

  • Medical necessity letter addresses FDA indication
  • Infusion site and monitoring plan specified
  • Prior corticosteroid use documented
  • All required forms completed and signed

New Jersey Appeals Process

If Aetna CVS Health denies your Vyondys 53 prior authorization, New Jersey offers robust appeal rights through the Independent Health Care Appeals Program (IHCAP).

Internal Appeals with Aetna

  1. First-level appeal: 180 days from denial notice
  2. Standard review: 30 days for decision
  3. Expedited review: 72 hours if delay risks serious harm
  4. Second-level: Independent reviewer within Aetna network

External Appeal via IHCAP

After exhausting Aetna's internal appeals, you can file with New Jersey's IHCAP:

  • Administrator: Maximus Federal Services
  • Deadline: 120 days from final internal denial
  • Cost: Free to patients
  • Success rate: Approximately 50% overturn rate for medical necessity denials
  • Timeline: 45 days standard, expedited available for urgent cases

Filing Requirements

Submit these documents to IHCAP:

  • Final denial notice from Aetna
  • Complete medical records including genetic testing
  • Neuromuscular specialist's medical necessity letter
  • Evidence of functional status and treatment goals
  • Any additional supporting literature

Contact Information

  • NJ DOBI Consumer Hotline: 1-800-446-7467
  • IHCAP-specific line: 1-888-393-1062

The IHCAP decision is binding on Aetna if favorable to the patient. Counterforce Health specializes in preparing comprehensive appeal packages that address specific denial reasons with targeted evidence.

FAQ

How long does Aetna CVS Health prior authorization take for Vyondys 53?
Standard decisions typically take 72 hours, with expedited reviews available within 24 hours if urgency is justified due to potential functional decline.

What if Vyondys 53 is not on Aetna's formulary?
File a formulary exception request with the same documentation required for prior authorization, emphasizing FDA approval and lack of therapeutic alternatives for exon 53-amenable DMD.

Can I request an expedited appeal in New Jersey?
Yes, both Aetna internal appeals and IHCAP external reviews offer expedited processes if delay would cause serious harm to the patient's health.

Does step therapy apply to Vyondys 53?
Some Aetna plans may require documentation of corticosteroid use, but step therapy through other exon-skipping drugs typically doesn't apply due to mutation-specific mechanisms.

What happens if I miss the appeal deadline?
Contact the NJ DOBI Consumer Hotline at 1-800-446-7467 immediately. In some cases, good cause exceptions may be available for missed deadlines.

How much does Vyondys 53 cost without insurance?
Guide prices show approximately $1,570.78 for a 2 mL vial, though actual costs vary. Sarepta Therapeutics offers patient assistance programs for eligible families.

Can my doctor file the external appeal for me?
Yes, New Jersey allows providers to file IHCAP appeals on behalf of patients with proper consent and authorization.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and clinical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. For assistance with complex prior authorization and appeal processes, Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.